All In Biotech

Drug Trial Radar · NCT07562581

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Jun 2029

Study completion Jun 2030

Sponsor

Sponsor type
Industry
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner

Conditions

  • Non-small Cell Lung Caner
  • KRAS-mutated
  • Metastasis
  • Previous Treamted

Interventions

  • luvometinib + anlotinibBiological

    Dose A:luvometinib 8mg and anlotinib 8mg; Dose B1:luvometinib 12mg and anlotinib 8mg; Dose B2: luvometinib 8mg and anlotinib 10mg; Dose C: luvometinib 12mg and anlotinib 10mg.

  • luvometinib + anlotinibBiological

    in this part, patients will receive the combined treatment of luvometinib and anlotinib at the recommended doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the objective response rate (ORR) per RECIST v1.1Time frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.